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DEFINITIONS/ABBREVIATIONS 
BIM = bisindolylmaleimide 
caly A = calyculin A 
CaMKII = Ca2+/calmodulin-dependent kinase II 
CM = cardiomyocyte 
cMLCK = cardiac myosin light chain kinase 
DMSO = dimethyl sulfoxide 
EGTA = ethylene glycol tetraacetic acid 
GPCR = G-protein-coupled receptor 
MHC = myosin heavy chain 
MLC-1 = myosin light chain 1/essential light chain (ELC) 
MLC-2 = myosin light chain 2/regulatory light chain (RLC) 
MLC-2-P = phosphorylated myosin light chain 2 
MLCK = myosin light chain kinase 
MLCP = myosin light chain phosphatase 
PKC = protein kinase C 
ROCK = Rho kinase 
skMLCK = skeletal muscle MLCK 
smMLCK = smooth muscle MLCK 
stsp = staurosporine 
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Regulation of cardiac function in terms of contractility, beating frequency, blood supply 
and metabolic rates, relies on a three-tiered control system: i) immediate and fast 
feedback in response to mechanical load on a beat-to-beat basis (Frank-Starling relation), 
ii) more sustained regulation involving transmitters and hormones as primary messengers 
and iii) long-term adaptation by changes in the gene expression profile. The more 
sustained signalling mode involves a wide variety of biologically active molecules 
mediating their effects through receptors in the heart. Signal transduction pathways link 
the events on the cell surface with various effector mechanisms within the 
cardiomyocyte, including modulation of the contractile apparatus [1]. This thesis aims at 
elucidating aspects of how the phosphorylation of the small protein myosin light chain 2 
(MLC-2) is regulated, and its possible role in modulating contraction of the heart.   
Cardiac muscle; anatomy and physiology 
Cardiac muscle is a type of muscle tissue found only in the walls of the heart. It is similar 
to skeletal muscle with respect to being striated and similar to smooth muscle with 
respect to the nuclei being centrally located and many cells are required to span the 
length of the muscle. It differs from both skeletal muscle and smooth muscle in that its 
cells branch and are joined to one another via intercalated disks; densely staining 
transverse bands that characteristically appear at right angles to the long axis of the 
cardiac myofibers, and that represent specialized cell-cell junctions that contain regions 
of low electrical resistance. This allows communication between the cells producing a 
sequential contraction of the cells from the bottom of the ventricle to the top. Although 
not a true anatomical syncytium, the heart functions as if all of the cardiomyocytes are in 
free electrical communication [2].  
Cardiomyocytes
Although cardiomyocytes represent most of the myocardial mass, approximately 70% of 
the cells are smaller nonmyocytes including vascular smooth muscle cells, endothelial 
cells and fibroblasts. Also, there are several types of cardiomyocytes within the adult 
human heart. The most numerous are working cardiomyocytes of the atria and ventricles 
that are specialized for contraction. Atrial cardiomyocytes are smaller in diameter than 
those of the ventricles. Purkinje fibers, found in the AV bundle, bundle branch and 
ventricular endocardium, are large cells specialized for rapid conduction. The SA and AV 
node are networks of small, sparsely cross-striated nodal cells [2].  
The sarcomere 
The contractile proteins, which make up almost 50% of the volume of working 
cardiomyocytes, are organized in a regular array of cross-striated myofibrils. The 
fundamental morphological unit of striated muscle is the sarcomere, defined as the region 
between two Z lines (figure 1).  
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Figure 1: Simplistic model of a sarcomere. 
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The thick filaments that extend the length of the A-band are polymers of myosin and titin. 
The central regions of the thick filaments also contain myosin-binding protein C, M-
protein, myomesin and an isoform of creatine phosphokinase. The thin filaments are 
double-stranded actin polymers that include tropomyosin and the three proteins of the 
troponin complex; troponin T, C and I. At the Z lines, the thin filaments are interwoven 
with several cytoskeletal proteins, including -actinin, Cap Z (-actinin), nebulette and 
desmin, which attach the sarcomeres to cell adhesion molecules that link myocytes to 
each other and to the extracellular matrix [2].  
Myosins are motor proteins known to play fundamental roles in many forms of 
eukaryotic motility such as cell crawling, cytokineses, phagocytosis, maintenance of cell 
shape, and organelle/particle trafficking [3]. Although actin polymerization alone can 
drive some forms of motility, myosins appear to power a wide variety of movements and 
are important in processes such as signal transduction [4] and establishment of polarity 
[5]. 
Members of the myosin superfamily are defined by the presence of a heavy chain 
with a conserved catalytic domain. In most myosins, the catalytic domain is followed by 
an -helical light chain-binding region consisting of one or more IQ motifs, and a C- 
and/or an N-terminal extension thought to endow class-specific properties such as 
membrane binding or kinase activity [3].  
In the human heart, two sarcomeric myosin II genes are expressed, generating two 
isoenzymes of myosin heavy chain (MHC) (designated - and -MHC), which share 93% 
structural homology in the rat [6]. The relative proportion of - and -MHC depends on 
species, age, hormonal balance and cardiovascular stress [7-11]. More specifically, small 
mammals such as adult rodents (e.g. mouse and rat) predominantly express -MHC in the 
ventricle, whereas larger mammals (e.g. rabbits and humans) predominantly express -
MHC [12]. In rodents, -MHC reveals a lower ATPase activity than -MHC and is 
associated with a lower maximal shortening velocity of the cardiac fibers [13, 14].  
Human cardiac muscle myosin is a hexameric protein of 520 kDa, consisting of 
two heavy chains (MHC, ~220 kDa) and two pairs of light chains (MLC): the essential 
light chain (MLC-1/ELC, alkali MLC, ~20 kDa) and the regulatory light chain (MLC-
2/RLC, 5,5-dithio-bis-(2-nitro-benzoate)-MLC, ~22 kDa). Each MLC is bound to an -
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helix (lever arm) that links the globular N-terminal head domain (~120 kDa) to the rod 
portion (~100 kDa). Beneath the lever arm the two MHC molecules, together with the 
associated light chains, form an -helical coiled-coil that extends into the thick filament 
backbone. There, double-stranded myosin molecules anneal with adjacent double-
stranded myosin molecules, entering the stack at 14.3 nm intervals, 3 pairs of heads, 
arrayed at 120 intervals in cross-section. A pair of myosin heads is stationed every 42.9 
nm, up to the mid point (M-line), where the polarity of the myosin reverses so that the 
summed forces of the actomyosin cross-bridges in the thick filament serve to shorten the 
sarcomere [15].  
The actomyosin motor 
The actomyosin motor consists of two parts: the head region of myosin that extend from 
the thick filament surface, and actin monomers of adjacent thin filaments, to which the 
myosin heads bind during force generation and muscle shortening. The motor is fueled by 
MgATP, and regulated by Ca2+ which has evolved as a global intracellular messenger for 
signal transduction by reversible binding to Ca2+-sensing proteins. Inside the 
cardiomyocyte, ion pumps, ion exchangers and channels keep the cytoplasmic calcium 
level at rest around ~100 nM which is more than 10,000-fold lower than outside the cell 
(>10-3 M). Upon cell membrane depolarization, the cytoplasmic Ca2+ concentration 
increases about 20-fold to above 1-10 M, happening in the range of milliseconds [1, 16]. 
Upon depolarization of the transverse tubular membrane (invaginations of the 
sarcolemma at the Z lines), there is influx of Ca2+ through the voltage sensitive slow 
inward Ca2+-channel that triggers Ca2+ release from the ryanodine receptor (Ca2+-release 
channel of the sarcoplasmic reticulum (SR)). Ca2+ activates the troponin-tropomyosin 
complex on actin-containing thin filament, thereby opening target sites on actin 
monomers to myosin head binding. The myosin head contains a crucial nucleotide-
binding site to which MgATP binds. The enzymatic activity of myosin helps water split 
the terminal phosphate from the ATP by breaking the covalent bond. The products of 
MgATP2-, MgADP1- and Pi2-, remains bound, and the myosin head binds to actin via 
weak ionic interactions at specific residues at the myosin-actin interface. Ca2+-regulated 
movement of tropomyosin allows hydrophobic interactions to occur between myosin and 
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actin, thereby creating a much tighter bond [15, 17, 18]. When myosin binds to actin, an 
ATP-dependent conformational change in the myosin molecule results in movement of 
the actin filaments towards the centre of the sarcomere. This movement, also known as 
the cross-bridge cycle, shortens the length of the sarcomere and leads to contraction of 
the muscle fibre. 
Recently, an interesting discovery was made concerning the anatomy of the 
cardiomyocytes. Wu and Bers [19] demonstrated that the SR lumen is highly 
interconnected with the nuclear envelope and also with distant regions of the SR. 
Moreover, the SR-nuclear envelope throughout the cardiomyocyte appears to be a single 
large continuous Ca2+ storage compartment. This provides a spatially uniform driving 
force for SR Ca2+ release throughout the cardiomyocyte during depolarization, and may 
be important in producing a homogeneous and synchronous Ca2+ release and contractile 
activation. Additionally, it might connect cytoplasmic and nuclear events, e.g. contraction 
and gene expression. 
Myosin light chain 
In the human heart, two different genes encode MLC-1 isoforms; an atrium-specific and a 
ventricle-specific. Ventricular MLC-1 is the same isoform as the MLC-1 present in the 
adult slow skeletal muscle [20]. MLC-2 also exists in an atrial and ventricular isoform, 
but in contrast to MLC-1, MLC-2 can be phosphorylated. Furthermore, sequence 
analyses in humans and various animal species suggest the existence of two ventricular 
MLC-2 isoforms (MLC-2 and MLC-2*) having the same molecular weight but different 
isoelectric points (MLC-2* being more acidic) [20, 21]. MLC-2* is the dominant isoform 
expressed in humans (ratio 2.3 to MLC-2) [22]. Adult rat and mouse appear to be an 
exception having only two isoforms (MLC-1 and MLC-2) [23]. Together with 
calmodulin and troponin C, the myosin light chains belong to the superfamily of EF-hand 
Ca2+ binding proteins [24]. Post-translational modifications other than phosphorylation 
have also been identified in the functionally important N-terminal site of MLC-2. In 
normal hearts, both phosphorylation and deamidation (the latter is thought to account for 
the acidic shift in MLC-2*) have been documented, whereas N-terminal truncation has 
been associated with ischemia/reperfusion [25]. 
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All striated muscles make use of molecular mechanisms that help positioning the 
myosin heads for optimal force and power output. Studies in animals have revealed that a 
key determinant is the surface-to-surface distance between thick and thin filaments [26-
28].  Phosphorylation of MLC-2 at Ser15 results in the addition of negative charge to the 
N-terminal region of MLC-2. This causes the myosin heads to swing out from the thick 
filament backbone towards the actin filament (the “order to disorder” transition), thereby 
increasing the probability of attachment to actin and promoting force generation (figure 
2) [29, 30]. This fine-tuned steric translocation of the myosin head is the basis for Ca2+ 
sensitisation. MLC-2 phosphorylation-induced Ca2+ sensitization has no effect upon 
steady-state isometric force at saturating concentrations of Ca2+, but only at 











Figure 2: The mechanism of Ca2+ sensitization through MLC-2 phosphorylation. Red 
arrows indicate the elevation of the S1 fragment away from the myosin backbone and 
closer to the actin filaments. 
 
 In cardiac tissue, MLC-2 phosphorylation (Ser15) leads to modulation of cardiac 
muscle contraction. Positive inotropic effects after treatment with agonists for 1-
adrenoceptors (1-AR) [34], endothelin [35] and prostanoid F receptors [36], and for 5-
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HT2A [37] and muscarinic M2 receptors [38] in normal and failing hearts, respectively, 
are thought to be dependent on MLC-2 phosphorylation. Thus, MLC-2 phosphorylation 
facilitates contraction and mediates inotropic responses to various neurohumoral stimuli 
in the heart. For comparison, in smooth muscle, contractility is induced by the 
phosphorylation of MLC-2 (Ser19) [39]. 
In vivo hearts have been shown to exhibit a spatial gradient of decreasing vMLC-
2 phosphorylation across the chamber wall from the epicardium and apex towards the 
endocardium, which is thought to facilitate a torsional contraction with higher contractile 
force at the wall surface than close to the cavity [40]. 
 MLC-2 has also been identified as an essential component of sarcomere assembly 
and contractility in the vertebrate heart [41, 42]. Transgenic mice expressing a non-
phosphorylatable ventricular isoform display no Ca2+-senitization, and long-term effects 
involve generally reduced cardiac function [43, 44]. The identification of MLC-2 
mutations linked to familial hypertrophic cardiomyopathy [45, 46] underscores the 
importance of understanding its actions as a regulator of contraction and cellular 
organization, and also understanding how the protein itself is regulated. 
Protein kinases 
Protein kinases are key regulators of cell function, and constitute one of the largest and 
most functionally diverse gene families. By removing a phosphate group from ATP and 
covalently attaching it to an amino acid that has a free hydroxyl group, providing a 
phosphate ester, they direct the activity, localization and overall function of many 
proteins, and serve to orchestrate the activity of almost all cellular processes [47]. 
Proteins can be phosphorylated on nine different amino acids (tyrosine, serine, threonine, 
cysteine, arginine, lysine, aspartate, glutamate and histidine) with serine, threonine and 
tyrosine phosphorylation being predominant in eukaryotic cells [48]. Protein kinases can 
be classified by the nature of their substrate. The by far largest group, serine/threonine 
specific kinases, can be further classified based on their activators; e.g. cAMP-dependent, 
cGMP-dependent, Ca2+/calmodulin-dependent or Ca2+/phospholipid-dependent (PKC). 
Each of these subclasses may include several isoenzymes [49]. 
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Regulation and inhibition of protein kinases 
Because protein kinases have profound effects on a cell, their activity is highly regulated. 
Kinases are turned on or off by 1) phosphorylation, 2) binding of activator or inhibitor 
proteins, 3) binding of small molecules, or 4) controlling their location in the cell relative 
to their substrates. Deregulated kinase activity is a frequent cause of disease, particularly 
cancer, since kinases regulate many aspects that control cell growth, movement and death 
[50]. 
 Most kinase inhibitors discovered to date are ATP competitive and present one to 
three hydrogen bonds to the amino acids located in the hinge region of the target kinase, 
thereby mimicking the hydrogen bonds that are normally formed by the adenine ring of 
ATP. Type 1 inhibitors, constituting the majority of ATP-competitive inhibitors, 
recognize the so-called active conformation of the kinase, a conformation otherwise 
conducive to phosphotransfer. Unfortunately, the ATP-binding site within the 
serine/threonine kinase group displays striking homology. Inhibitors acting on this site 
are therefore unlikely to show a high degree of selectivity. Type 2 inhibitors recognize 
the inactive conformation of the kinase. Allosteric inhibitors bind outside the ATP-
binding site, and modulate kinase activity in an allosteric manner. Inhibitors in this 
category tend to exhibit the highest degree of kinase selectivity because they exploit 
binding sites and regulatory mechanisms unique to a particular kinase. Covalent 
inhibitors are capable of forming an irreversible, covalent bond to the kinase active site, 
most frequently by reacting with a nucleophilic cysteine residue [47]. 
Myosin light chain kinase 
Cardiac MLCK (cMLCK) was recently discovered as a new player in the regulation of 
MLC-2 in the heart [42, 51]. Before that, skeletal muscle MLCK (skMLCK) and smooth 
muscle MLCK (smMLCK) were thought to be responsible for the observed MLC-2 
phosphorylation. A common feature of all three MLCKs is the dedication to one 
substrate: MLC-2 [16]. The smMLCK gene expresses three transcripts in a tissue-specific 
manner. The short form is expressed in smooth muscle, but also in cardiac muscle at 
lower levels. The long form is found in smooth muscle cells in culture, embryonic 
smooth muscle and non-muscle cells. The third transcript, containing only the C-terminal 
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immunoglobulin module, is expressed in phasic smooth muscle tissues [52]. Likewise, 
skMLCK is predominantly expressed in skeletal muscle, but also detected in cardiac 
muscle [40, 53], although its abundance has been controversial [54]. However, ablation 
of the skMLCK gene in mice resulted in no changes in cardiac MLC-2 phosphorylation, 
but the mice failed to increase MLC-2 phosphorylation in skeletal muscle in response to 
repetitive electric stimulation [55]. Similarly, ablation of the long form of smMLCK did 
not affect cardiac MLC-2 phosphorylation either [56]. Together, these findings lay the 
groundwork for an expectation of a cardiac isoform of MLCK.  
 Rat cMLCK (795 aa, 86 kDa) consists of a conserved kinase domain including an 
ATP-binding site at the C terminus, with 58% identity with skMLCK and 44% identity 
with smMLCK. However, the N terminal domain is unique, with no significant homology 
to other known proteins. It is expressed only in the heart; in both atrium and ventricle. In 
rat neonatal heart, it was expressed 9- to 18-fold more abundantly than smMLCK. It 
colocalized with actin, but surprisingly not with MLC-2. The most unexpected finding 
though, was the phosphorylation of MLC-2 in a Ca2+/calmodulin-independent way [51], 
in contrast to the human cMLCK which was found to be Ca2+/calmodulin-dependent 
[42]. Rat cMLCK had a high affinity and relatively low catalytic efficiency to MLC-2, 
suggesting it may serve to maintain basal MLCK activity in the heart [57]. This was 
supported by the fact that overexpression of cMLCK led to enhanced MLC-2 
phosphorylation, whereas downregulation decreased steady-state level of MLC-2 
phosphorylation. The striking difference in Ca2+/calmodulin-dependency may simply be 
attributable to species differences, but in vitro assessment may not be sufficient to resolve 
this issue. Thus, we must await studies from genetically manipulated animals such as 
cMLCK deficient or overexpressing mice [57]. 
Protein phosphatases 
Eukaryotic protein phosphatases are structurally and functionally diverse enzymes that 
are represented by three distinct gene families. The phosphoprotein phosphatase (PPP and 
PPM) families encode protein Ser/Thr phosphatases, whereas the protein tyrosine 
phosphatase (PTP) family includes both tyrosine-specific and dual-specificity (Ser/Thr 
and tyrosine) phosphatases. Within each superfamily, considerable structural diversity is 
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achieved by the attachment of regulatory and targeting domains and/or subunits to the 
protein catalytic domain, forming a variety of holoenzymes. PP1, PP2A and PP2B of the 
PPP family, together with PP2C of the PPM family, account for the majority of the 
Ser/Thr phosphatase activity in vivo [58].  
 Phosphatases are highly regulated proteins, but it is important to make a clear 
distinction between the terms “regulators” and “inhibitors”. Regulatory subunits serve to 
localize the enzyme to particular subcellular localizations and modulate protein 
selectivity. More specifically, the catalytic subunits can bind a host of regulators, and 
several heterotrimeric PP1 complexes have been observed [59, 60]. Organisms also 
express different regulatory subunits in different tissues at different times [61, 62], in 
addition to undergoing multi site phosphorylation with each site having a unique effect 
on substrate activity [63]. Inhibitors, on the other side, appear to inhibit phosphatase 
activity against a wider array of substrates [64], by mechanisms such as e.g. physical 
occlusion of the catalytic site [65].  
 PP1 and PP2A are strongly inhibited by a diverse array of natural occurring 
toxins, e.g. polyether polyketides such as okadaic acid [66, 67] and tautomycin [68], 
nonribosomal peptides represented by microcystin LR [69, 70], and 
polyketide/nonribosomal peptides such as calyculin A [71]. Calyculin A, initially isolated 
from the marine sponge Discodermia calyx, was found to inhibit PP1 and PP2A with IC50 
values of 2 nM and 0.5-1.0 nM, respectively [72]. It consists of a polyketide and a 
dipeptide with a phosphate group in the polyketide portion (figure 3) [73]. X-ray 
crystallography has revealed that calyculin A binds to PP1 in a hydrophobic groove and 
an acidic groove on the surface of PP1. Calyculin A therefore recognizes PP1 by both 
hydrophobic and hydrophilic interactions, and the recognition site formed by the grooves 






Figure 3: Structural formula of calyculin A, a phosphatase 1 and 2A inhibitor. Adapted 
from Kita et al. 2002 [74]. 
 
Myosin light chain phosphatase 
MLCP is composed of three subunits: the catalytic subunit PP1c, a targeting subunit 
termed myosin phosphatase target subunit (MYPT) and a smaller subunit of unknown 
function. Most of the properties of myosin light chain phosphatase are due to MYPT and 
include binding of PP1c and substrate. The MYPT family consist of five molecules; 
MYPT1, MYPT2, MBS85, MYPT3 and TIMAP (TGF--inhibited membrane associated 
protein). MYPT1 is expressed in many tissues although present in higher concentrations 
in smooth muscle [75]. Some years ago, MYPT 2 (110 kDa) was cloned, and found to be 
present in heart and brain [76]. In mouse heart, the ratios of MYPT2:MYPT1:MBS85 
were 10:2.7:1, respectively. Further characterization described the holoenzyme of 
cardiac/skeletal muscle MLCP (cMLCP) as composed of the catalytic subunit PP1c, and 
the two regulatory subunits HS-M21 and MYPT2 [77]. cMLCP was shown to display an 
overall identity of 61% with smMLCP, it was located close to the Z-line, it bound to the 
active form of RhoA, and was phosphorylated (Thr646) by Rho kinase with associated 
inhibition of the MYPT2-PP1c complex.  
The link between extracellular stimuli and cellular responses 
Intracellular signalling coordinates life sustaining cellular processes as diverse as growth, 
differentiation, maintenance of specific cell functions, energy production, protective 
responses to various types of extracellular stressors, and, if rescue operations fail, even 
energy consuming programmed death by apoptosis. Stimuli for these various processes 
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reach the cell in the form of extracellular primary messengers like transmitters (e.g. 
acetycholine, norepinephrine, serotonin) and hormones (e.g. epinephrine, dopamine, 
angiotensin-II, endothelin, growth factors, cell mediators) via the blood [1]. Cellular 
responses like contractility of the heart and regulation of kinases and phosphatases are the 
consequences of transmission of the extracellular stimuli through G-protein-coupled 
receptors and G proteins.  
G-protein-coupled receptors 
G-protein-coupled receptors (GPCR, heptahelical receptors) are the single most diverse 
class of cell surface receptors, which bind the extracellular primary messengers. 
Characteristic for the GPCR superfamily of cell surface receptors are their seven 
transmembrane(TM)-spanning -helices connected by three intracellular (i1-3) and three 
extracellular (e1-3) loops. Most GPCRs have two cysteine residues which form a 
disulfide bond important in packing and stabilising of a restricted number of 
conformations of these seven TMs. Aside from sequence variation, GPCRs differ in the 
length and function of their extracellular N-terminus, intracellular C-terminal tail, and 
their intracellular loops. Each of these domains provides specific properties. Besides 
transmission of extracellular signals, the GPCR’s activity is modulated by cellular signals 
in an auto- or transregulatory fashion [78]. The transition from inactive to active 
conformation of the receptor is associated with a change in the relative orientation of the 
seven TMs, which reveals sites for G protein recognition and activation. The fine-tuning 
of their coupling to G proteins is regulated by splicing, RNA editing and 
phosphorylation. Some GPCRs have been found to form either homodimers or 
heterodimers with a structurally different GPCR, but also with membrane-bound proteins 
having one transmembrane domain. Finally, a few GPCRs are unfaithful to G proteins 
and interact directly, via their C-terminal domain, with proteins containing PDZ and 
Enabled/VASP homology (EVH)-like domains [78]. 
G proteins 
Heterotrimeric guanine nucleotide-binding proteins (G proteins; subunits ,  and ) 
couple the activation of GPCR receptors to the intracellular signalling pathways. As the 
primary intermediary between receptors and effectors, G proteins play a critical role in 
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determining the specificity and temporal characteristics of the cellular responses to a 
diverse array of extracellular stimuli [79]. Receptors catalyze exchange of tightly bound 
GDP for GTP on the  subunit in a process that requires the complete heterotrimer. This 
is the rate-limiting step in G protein activation. Once GDP is released, a stable, high-
affinity complex between the activated receptor and G protein is formed. Binding of GTP 
to G destabilizes this complex allowing both subunits (G-GTP) and G to interact 
with downstream effector proteins. The activation is terminated by the hydrolysis of GTP 
by the GTPase activity inherent to the G subunit. The GDP-bound  subunit then 
reassociates with the  complex and is ready to enter a new activation cycle [80].  
The G subunit classify G proteins into 4 primary families: Gs, Gq/11, G12/13 
and Gi/o. Common to Gs family members are their capability to activate adenylyl 
cyclases, and thereby causing an increase in 3’,5’-cyclic adenosine monophosphate 
(cAMP). The Gs is ubiquitously expressed, and is known to couple to 1- and 2-
adrenoceptors in the heart. Gq/11 is also ubiquitously expressed in mammals. A wide 
variety of receptors in the heart couple to this G protein family, including 1-
adrenoceptors, endothelin-, urotensin-II-, 5-HT2A-, and angiotensin receptors, and they all 
result in an increased intracellular concentration of PLC-. The G12/13 family of 
heterotrimeric G proteins couple receptors to Rho guanine-nucleotide-exchange factors 
(RhoGEF) resulting in the activation of Rho A. Many GPCRs have been shown to 
mediate G12/13 activation. For some receptors a selective coupling has been demonstrated, 
but with a few exceptions G12/13-coupled receptors also interact with Gq/11, and, in some 
cases, also with Gi-type G proteins. Thus a typical feature of G12/13-mediated signalling 
events is that they are usually initiated in parallel with Gq/11-mediated processes. Gi/o are 
ubiquitously expressed and are classically associated with the inhibition of adenylyl 
cyclase (AC). Of the three Gi isoforms (Gi1, Gi2, Gi3), Gi2 is the predominant isoform in 
cardiomyocytes. Gi2 and Gi3 have both been shown to couple to cardiac 2-ARs [81]. Gi 
has also been suggested to couple to muscarinic M2 receptors [38, 82]. 
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AIMS OF THE THESIS 
The overall aim of the thesis was to elucidate aspects of how phosphorylation of cardiac 
MLC-2 is regulated and its modulatory role in heart contraction. More specifically, we 
wanted to: 
1. develop a method to estimate and evaluate the efficacy of selective enzyme 
inhibitors used in the study of cell signalling in cardiomyocytes/cardiac tissue 
(paper I) 
2. study and compare which kinase activities are involved in the basal 
phosphorylation of MLC-2 in quiescent and electrically stimulated 
cardiomyocytes (paper II + III) 
3. investigate the relevance of cultured primary cardiomyocytes as a model system 
for the intact beating heart muscle (paper II +III) 
4. elucidate some aspects of the signalling pathways involved in agonist-induced 
GPCR-stimulation in cardiomyocytes, preferentially through Gq/11-coupled 
receptors (paper III) 
5. investigate the role of MLC-2 phosphorylation in the positive inotropic effect 
observed after calyculin A stimulation (paper III) and muscarinic receptor 
activation (paper IV) 
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SUMMARY OF THE PAPERS INCLUDED 
Paper I 
In this paper, we presented and discussed a method for calculating the reaction rate 
constants and, thus, for evaluating the efficacy of one or more inhibitors when introduced 
to a forward-backward pair of enzymatic reactions. For example, in an apparent 
equilibrium process, reactant A can react into reactant B and vice versa, where E1 is the 
enzyme converting A into B, and E2 is the enzyme converting B into A. The dynamic 
steady state of the process is then dependent on the activities of E1 and E2. If one of the 
enzymes is selectively inhibited, the balance between the two enzyme activities is shifted 
and new apparent steady states are elicited thus making it possible to calculate the 
reaction rate constants.  
 As an example, reaction rate constants were calculated for the phosphorylation 
and dephosphorylation reaction of MLC-2 in isolated quiescent cardiomyocytes. The 
phosphorylation reaction rate was found to be one-fifth the rate constant of the 
dephosphorylation in basal steady state. However, in the presence of calyculin A, a 
phosphatase 1 and 2A inhibitor, this balance was shifted. The new apparent rate constant 
of the residual phosphatase activity was only one-third the rate constant of the kinase 
activity. Calyculin A (10-7 M) was also found to inhibit phosphatase activity by 93%, 
important knowledge in the further usage of this compound. 
 The method depends on knowing (i) the ratio [A]0/[B]0 in basal condition, and (ii) 
the changes occurring after the addition of the inhibitor. A prerequisite is that A and B 
are not subjected to any other conversions. The calculations are adjusted to apply for both 
zero-order and first-order enzyme kinetics. The method’s foremost advantage is to 
provide valuable information when assessing reactions, and improve calculation and 
interpretation of generated data in a precise, easy and low-cost manner. 
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Paper II 
The primary objective of paper II was to investigate which kinase activities are involved 
in the basal phosphorylation of MLC-2 in rat quiescent cardiomyocytes without agonists 
present. By maximally inhibiting MLCP, all changes in phosphorylation reflect the action 
of kinase activities. This, in combination with preincubating the cardiomyocytes with a 
non-selective kinase inhibitor, revealed a complex concentration-response curve. Having 
two components with IC50-values separated by more than two log units, the curve clearly 
indicated two kinetically different groups of kinase activities. Preincubation in the 
absence and presence of various selective protein kinase inhibitors alone and in 
combinations indicated the presence of at least three active kinases; CaMKII, a 
Ca2+/calmodulin-dependent and a Ca2+/calmodulin-independent kinase activity. This is, 
to our knowledge, the first report that CaMKII phosphorylates MLC-2 in 
cardiomyocytes. The surprising lack of effect of two different MLCK inhibitors 
suggested an insignificant role of MLCK, the enzyme so far believed to be the only 
MLC-2 kinase operating in the heart. We also conclude that neither PKC nor Rho kinase 
phosphorylate MLC-2 in quiescent cardiomyocytes.  
Paper III 
In paper III we investigated aspects of in situ MLC-2 phosphorylation in models of 
electrically stimulated adult rat cardiomyocytes in culture and rat ventricular muscle 
strips ex vivo. Previous findings (paper II) in quiescent cardiomyocytes demonstrated a 
lack of MLCK activity, but a significant role for CaMKII in combination with two 
unidentified kinase activities not caused by PKC or Rho kinase. Here we show how 
MLCK is recruited in electrically stimulated cardiomyocytes in the presence of Ca2+ 
transients, by observing a 41.7% reduction in MLC-2 phosphorylation reaction rate after 
selective MLCK inhibition (by ML-7). CaMKII, identified by selective inhibition by KN-
93, was also found to act as an MLC-2 kinase in this model, together with an unidentified 
Ca2+/calmodulin-independent kinase activity insensitive to staurosporine and PKC 
inhibition. The kinase activities were revealed under maximal phosphatase inhibition by 
calyculin A (10-7 M). 
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 No significant effects of agonists (phenylephrine, fluprostenol and carbachol) 
were observed in the cardiomyocytes beyond the effect of calyculin A, although the 
apparent numerical ML-7 sensitivity increased in the presence of phenylephrine and 
fluprostenol. By comparison, calyculin A induced a sustained positive inotropic effect in 
muscle strips which could be abolished by ML-7 preincubation. The inotropic effect 
correlated with levels of MLC-2 phosphorylation as measured in frozen preparations. 
Taken together, the present results clearly demonstrate a key role for MLCK as an MLC-
2 kinase in both electrically stimulated cardiomyocytes and muscle strips. The latter 
model also suggests a role for MLC-2 phosphorylation in mediating calyculin A-induced 
increase in contraction. 
Paper IV 
The study in paper IV was designed to characterize an observed carbachol-induced 
positive inotropic effect in ventricular muscle from rats with congestive heart failure, and 
elucidate the mechanism of action. The inotropic response, which was not seen in sham-
operated rats, did not correlate with infarction size, but did correlate with increased left 
ventricular end diastolic pressure, heart weight/body weight ratio and lung weight, 
primary indicators of the severity of heart failure. Antagonizing the carbachol-evoked 
response produced the expected potency shift only when using selective M2-receptor 
antagonists. The response was also abolished by pertussis toxin pretreatment, an indicator 
of Gi-coupling and hence further supporting a role for the M2 receptor in the mediation of 
the inotropic response. The inotropic effect revealed an increase in myofilament Ca2+-
sensitivity through increased MLC-2 phosphorylation, which could be reversed by 
inhibitors of both Rho kinase and MLCK.  
 This is the first report to show that activation of muscarinic receptors, most likely 
M2 receptors, increased contractility in failing but not sham-operated rat ventricles, by 
increasing MLC-2 phosphorylation. Shifting to this less energy-demanding mechanism of 
inotropic support may be particularly advantageous in failing hearts. 
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RESULTS AND DISCUSSION 
Methodological considerations 
Cell cultures 
All cells and muscle tissue used in this thesis originate from male Wistar rats (out-bread 
strain). The final cell cultures consisted of >95% ventricular, elongated, striated, non-
contracting cardiomyocytes as observed in the microscope (figure 4). Due to gradient 
centrifugation during the isolation protocol, contamination from fibroblasts was not a 
problem, and the last <5% were mainly rounded-up cardiomyocytes.  
 
Figure 4: Adult rat ventricular cardiomyocytes in culture. Photographed by H. Eikemo. 
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There are several advantages in using cell cultures when studying regulation of cardiac 
function and signalling. Firstly, it is a widely used model system which makes it 
comparable between different laboratories. Secondly, one does not have to deal with 
neurotransmitter release observed in whole muscle tissue sample, which facilitates 
studies on basal steady-state conditions. Also, a high number of interventions can 
potentially be executed on the same cell population, controlling nicely for variation 
within the assay and facilitating paired comparisons. Disadvantages include the un-
physiological state by not having i) cell-cell-junctions, ii) an intact extra-cellular matrix 
(peeled off during collagenase treatment), and iii) contact with e.g. fibroblasts and other 
cell types normally interacting together. Studies on co-cultures between cardiomyocytes 
and fibroblasts have been performed and compared to monocultures. The results showed 
a different response-pattern, indicating that the cross-talk between cell types is not 
unimportant [83]. 
 In isolated quiescent adult cardiomyocytes, as used in papers I and II, the 
concentration of intracellular Ca2+ is fairly stable without Ca2+-transients, and no 
spontaneous contraction is observed. This situation of cellular components makes it a 
good model for disclosing and studying Ca2+-transient-independent processes in situ 
which may otherwise be masked by or secondary to Ca2+ transient-dependent processes 
in the contracting cardiomyocyte or beating myocardium. Experiments on quiescent cells 
were performed ~20 h after isolation, whereas studies on contracting cells (paper III) 
were performed on newly isolated cells (<3 h). Apparently, the cardiomyocytes lost the 
ability to respond to electrical stimulation after a period of 20 h quiescence.  
 Observing electrically stimulated cardiomyocytes in the microscope during kinase 
inhibition, striking dissimilarities were seen with regard to morphology and contraction 
pattern. After 40 min of calyculin A incubation, ~50% of control cells (no kinase 
inhibitor present) had disturbed morphology (cells were rounded up) and irregular 
contraction pattern. W7 preincubation preserved an intact morphology, but removed all 
contraction. ML-7 preincubation however, caused a marked loss of the cell’s striated and 
elongated form, and also influenced the contraction by partly inhibiting it and partly 
making it irregular. So, it seems that calmodulin inhibition protects the cells from losing 
their original morphology, whereas MLCK inhibition speeds up the process of sarcomere 
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disorganization/disruption. This is in line with previous reports demonstrating an 
essential role of MLCK in sarcomere assembly [41, 42]. 
 Another interesting observation was how the cells preserved their morphology 
and contractility when electrical stimulation was started simultaneously with calyculin A 
addition. If electrical stimulation was started 5 min prior to calyculin A addition, which 
was the case in all experiments in paper III, the cells had a much higher tendency of 
rounding up and displaying a fibrillation-like contraction. These observations indicate a 
protective role of phosphatase inhibition. Nevertheless, the latter protocol was chosen 
since the cardiomyocytes needed approximately 4-5 min to get into rhythmical 
contraction after the onset of electrical stimulation. Furthermore, the cells lost their 
morphology if electrical stimulation was applied during all of the intervention time (i.e. 
during 45 min of kinase inhibition followed by up to 40 min of phosphatase inhibition). 
Therefore, starting electrical stimulation 5 min prior to calyculin A addition was a 
compromise. 
Muscle strips 
In papers III and IV, isometrically contracting left ventricular muscle strips were used 
[84]. Most cell types present in the ventricle is also present in this multicellular 
preparation. Thus the structural composition of the heart muscle tissue is intact with 
preserved cell-to-cell connections and an extracellular matrix. Despite the presence of 
non-cardiomyocytes, the functional mechanical response measured is cardiomyocyte-
specific. Taken together, muscle strips might represent a more physiologically relevant 
model system mimicking the intact beating heart, although extrapolation to in vivo 
conditions must be done with great caution. 
Western blotting and quantification 
Although not expressing absolute amounts of MLC-2 phosphorylation, the MLC-2 
phosphorylation assay has several advantages. The antibody used is highly vMLC-2 
specific and identifies both phosphorylated and non-phosphorylated forms 
simultaneously (recognizes residue 45 to 59, far away from the phosphorylated residue 
15) without the need to strip the membranes and hence risk losing some of the signal 
(figure 5). Furthermore, by calculating MLC-2 phosphorylated in relation to total MLC-2 
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within each sample, any potential differences in amount of protein loaded from lane to 
lane will be eradicated, thus giving a more accurate estimate. This was confirmed by 





Figure 5: Representative western blot where both phosphorylated and non-
phosphorylated MLC-2 have been identified. 
 
Percentile plots 
The percentile plot is obtained by normalizing the effector variable (e.g. MLC-2 
phosphorylation) from each experiment between 0 and 100, and the resulting values are 
used to calculate the percentile effect at each actual point of measurement (=x-axis, e.g. 
time or drug concentration). The curve is based on the x,y pairs corresponding to defined 
percentiles of the effector variable (e.g. 10, 20, 30 etc. percent) and plotted with the 
resulting curve, for illustration. This means that e.g. the x value of the 50 percentile 
indicates the time to half maximal effect [85]. The foremost advantage of using percentile 
plots is how it normalizes a set of experiments and makes them directly comparable even 
though e.g. basal values might vary. The method provides the curves with the appropriate 
slope which otherwise might be artificially shallow when estimated by simply averaging 
the responses at each concentration. 
Specificity and selectivity of protein kinase and phosphatase inhibitors 
There is considerable interest in the exploitation of selective protein kinase inhibitors for 
cell signalling studies. Many compounds reported to be selective have been examined 
and found to be so non-specific as to render meaningless any conclusions drawn from 
their use [86, 87]. In paper I we presented a method for estimating and evaluating the 
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efficacy of selective enzyme inhibitors, and demonstrated it on data from calyculin A-
induced MLC-2 phosphorylation. We found that in our model system of quiescent cells, 
10-7 M calyculin A inhibits MLCP 93%, which is indeed satisfactory from an 
experimental point of view. Staurosporine on the other hand, reduced MLC-2 
phosphorylation from 16.1%±1.8% (absence of staurosporine) to 9.7%±1.0% (presence 
of staurosporine), inhibiting only 47% before adding the phosphatase inhibitor. However, 
one must be careful when applying the method to such low numbers where minor 
changes have a big impact on the outcome. Interpretation of the results should always be 
seen in the light of the biology of the system. 
 Table 1 gives an overview of reported selectivity of the kinase inhibitors used in 
this thesis. All of the inhibitors are cell membrane permeable. Calyculin A binds 
reversibly to the catalytic site of MLCP, which is classified as a protein phosphatase 1 
[72]. BIM is a selective inhibitor of all PKC isoforms, with a ranked order of potency 
(>>>>	) [88]. 
 
Table 1: Inhibitory constants for the various protein kinase inhibitors. All values are 
given in M as Ki or, if indicated with *, as IC50. 
 
MLCK PKA PKC PKG CaMKII Rho kinase 
ML-9 3.8[89, 90] 32[90] 54[90]   # 









*0.018[94] *0.02[95]  




     
BIM   0.005-
0.07[88] 
   
KN-93     *1[98]  
#: 100 M of ML-9 reduces the kinase activity of Rho kinase by 77%, and 75 % and 46 % 
for smMLCK and skMLCK, respectively [86]. 
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Kinases involved in the phosphorylation of MLC-2 
By fully inhibiting MLCP by calyculin A (93% effective), as demonstrated in paper I, 
kinase activities involved in the phosphorylation of MLC-2 were successfully revealed. 
Maximal calyculin A-induced MLC-2 phosphorylation was roughly 60% and 80% in 
quiescent and contracting cardiomyocytes, respectively, and the reaction rate between 0 
and 40 min of calyculin A incubation was doubled (figure 6). This clearly demonstrates a 
higher general kinase activity in working cells, as would be expected in muscle strips ex 
vivo and in the intact beating heart in vivo.  
 






















Figure 6: The effect of maximal phosphatase inhibition by calyculin A in electrically 
stimulated vs. quiescent cardiomyocytes (CMs). Adapted from paper III. 
 
 One of the main findings in this thesis is that MLCK is recruited in situ going 
from a model of quiescent to contracting cells. From being completely inactive in resting 
cells, as demonstrated by a lack of effect of both ML-7 and ML-9, inhibition of MLCK 
accounted for a reduction of 41.7%±0.1% in MLC-2 phosphorylation reaction rate in 
electrically stimulated cells. Quiescent cells do not experience Ca2+-transients, but instead 
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have a relatively stable [Ca2+]i of around 100 nM. Absence or presence of Ca2+-transients 
is perhaps the key difference between the two model systems, and therefore likely the 
main reason for the recruitment of MLCK. However, the substantial effect of CaMKII 
inhibition also in quiescent cells suggested a role for Ca2+/calmodulin-dependent activity 
despite the absence of Ca2+-transients. These observations indicated that MLCK and 
CaMKII might have different requirements as to Ca2+-activating profiles. MLCK requires 
Ca2+ transients, whereas for CaMKII it is sufficient with a steady-state resting level of 
Ca2+. To our knowledge, papers II and III are the first reports demonstrating a role for 
CaMKII-mediated phosphorylation of MLC-2 in cardiomyocytes. 
Findings from papers II and III clearly demonstrate that different kinases are 
actively phosphorylating MLC-2 in different model systems. Two kinases remain un-
identified in quiescent cells (paper II): one that is Ca2+/calmodulin-dependent, and one 
that is not. Rho kinase, PKC and MLCK were ruled out as active kinases phosphorylating 
MLC-2. In electrically stimulated cells (paper III), a Ca2+/calmodulin-independent kinase 
activity remained unidentified. Therefore, looking to smooth muscle MLC-2 kinases, 
which have been much more extensively investigated than cardiac, might be helpful in 
getting some clues. Table 2 summarizes what is known so far in smooth muscle. 
The effect of CaMKII was described in paper II as a direct phosphorylation of 
MLC-2. However, CaMKII might also phosphorylate MLCK [99, 100]. In smMLCK, 
phosphorylation by CaMKII at a specific serine residue (site A) near the calmodulin-
binding domain, reduces the affinity of MLCK for Ca2+/calmodulin, indirectly reducing 
the phosphorylation of MLC-2 by MLCK [101]. The net effect of these two mechanisms 
is complex to predict, as it proposes that a Ca2+-dependent MLCK phosphorylation 
inhibits a Ca2+-dependent MLCK activity. However, it seems like the Ca2+ concentration 
partly decides which mechanism dominates, with higher concentrations needed for 














MLCK Ser19>Thr18 + [103] 
Integrin-linked kinase 
(ILK) 
Ser19=Thr18 - [104] 
Zipper-interacting 
protein kinase (ZIPK) 
Ser19=Thr18 - [105] 
Rho kinase Ser19 - [106] 
p21-activated kinase  
(PAK3) 
Ser19 - [107] 
CaMKII Ser19 + [108] 
p21-activated kinase  
(PAK2) 
Ser19 - [109] 
MAPKAP2 Ser19 - [110] 
p90 ribosomal s6  
kinase(RSK)-2 
Ser19 - [111] 
AIM-1 Ser19 - [112] 
 
Applying the theory described above to our data on quiescent cells, it can be 
hypothesized that low Ca2+ concentrations facilitate CaMKII-mediated MLC-2 
phosphorylation, and have no effect on MLCK phosphorylation nor MLCK recruitment. 
KN-93 would then reduce MLC-2 phosphorylation as opposed to ML-7. Indeed, this is in 
agreement with our observations. If we assume that increasing the Ca2+ concentrations, as 
is the case in electrically stimulated cells, enables CaMKII-mediated phosphorylation of 
both MLC-2 and MLCK but with a net effect of the former, then KN-93 would still 
reduce MLC-2 phosphorylation. At the same time, there would be a significant Ca2+ 
activation of MLCK laying the grounds for an effect of ML-7. This is in accordance with 
what we observed in the model of contracting cardiomyocytes (paper III). A further 
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reduction in MLC-2 phosphorylation was achieved by combining KN-93 and ML-7, 
although not an additive effect, and not larger than the reduction caused by staurosporine. 
The latter fits nicely with the fact that staurosporine is supposed to inhibit both CaMKII 
and MLCK at the concentrations used in our experiments.   
 The involvement of RSK-2 (table 2) can probably be excluded in this context 
since BIM is known to inhibit this kinase with IC50 values in the nanomolar range [113, 
114], and our data suggested no effects of BIM in neither quiescent nor contracting cells.  
As mentioned in paper II, staurosporine inhibits the Ca2+-independent ILK [115], ZIPK 
[105, 116] and PAK3 [117], all with IC50 values in the nanomolar range. In the quiescent 
cells, these kinases did probably not participate as MLC-2 kinases, as they would all fall 
into the fraction of high sensitivity to staurosporine which was found to be CaMKII-
mediated. In the contracting cells, the staurosporine-sensitive kinase activity had the 
same magnitude as ML-7 and KN-93 inhibition combined, suggesting no role for other 
staurosporine-sensitive kinases. 
 Rho kinase as a direct MLC-2 kinase was ruled out due to lack of effect of the 
selective inhibitor Y27632 in quiescent cells, and was not investigated in contracting 
cells. Documented effects of Rho kinase in cardiac cells consist of phosphorylation of the 
MLCP subunit MYPT, thereby inhibiting MLCP and hence increasing MLC-2 
phosphorylation [118]. However, since our kinase activity assay involved complete 
phosphatase inhibition, the latter effect of Rho kinase was not identified. 
 PAK2 has been shown to phosphorylate non-muscle MLC-2 in vitro [109], and 
MLCK in endothelial cells [119], and MAPKAP2 and AIM-1 have not been linked to 
cardiac tissue, thereby rendering their role in heart cells less likely than the previously 
described alternatives. 
 So which kinases are responsible for the observed MLC-2 kinase activities so far 
not identified? Far from all candidate MLC-2 kinases described in smooth muscle have 
been investigated in cardiac cells. One might speculate that some of the kinase activity 
might be due to the presence of cardiac specific kinases. Furthermore, the concept of 
indirect MLC-2 phosphorylation through regulation of direct MLC-2 kinases, as 
suggested for CaMKII, is also a possibility. 
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 In the context of unidentified kinases, it is tempting to bring up the identification 
of rat cMLCK which was, highly unexpectedly, found to phosphorylate MLC-2 in a 
Ca2+/calmodulin-independent way [51]. As mentioned in the introduction, cMLCK had a 
high affinity and relatively low catalytic efficiency towards MLC-2. This was suggested 
by the authors to serve to maintain basal MLCK activity in the heart, a suggestion 
supported by the fact that overexpression of cMLCK led to enhanced MLC-2 
phosphorylation, whereas downregulation decreased steady-state level of MLC-2 
phosphorylation. In the studies conducted in this thesis, we have assumed that ML-7 
inhibits all MLCK activity, and that MLCK activity is Ca2+/calmodulin-dependent. But if 
the cardiac isoform really is Ca2+/calmodulin-independent, and could escape the 
inhibitory effect (of both ML-7, ML-9 and staurosporine) due to structural deviation from 
the other MLCKs, it renders it as a hot candidate for the Ca2+/calmodulin-independent 
kinase activity.  
 The discussion of MLC-2 kinases involved in quiescent and contracting 






























Figure 7: Known (solid lines) and hypothesized (dotted lines) signalling pathways in the 
regulation of MLC-2 phosphorylation in quiescent cardiomyocytes. Red crosses indicate 


































Figure 8: Known (solid lines) and hypothesized (dotted lines) signalling pathways in the 
regulation of MLC-2 phosphorylation in electrically stimulated contracting 
cardiomyocytes. The red cross indicates that PKC is ruled out as a direct MLC-2 kinase 
by lack of effect of BIM. Rho kinase was not studied in this model. 
 
Role of MLC-2 phosphorylation in modulation of contraction 
Phosphorylation of Ser15 in MLC-2 [120] has been well documented to mediate Ca2+-
sensitization [33, 121, 122], and several studies suggest a role for this mechanism in 
modulation of contraction. Positive inotropic effects after treatment with agonists for 1-
adrenoceptors (1-AR) [34, 123], endothelin [35] and prostanoid F receptors [36] in 
normal hearts, and for 5-HT2A [37] and muscarinic M2 receptors [38] in failing hearts, are 
thought to be dependent on increased MLC-2 phosphorylation.  
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Calyculin A-induced positive inotropic effect in muscle strips 
In ventricular muscle strips ex vivo, calyculin A alone elicited a sustained positive 
inotropic response which was blunted by pre-treating the strips with ML-7. This suggests 
that the calyculin A-induced inotropic response is caused by MLCK-mediated 
phosphorylation of MLC-2. ML-7 alone did not lower basal contractile force, in contrast 
to the combined effect of ML-7 and calyculin A. The contraction-relaxation curves 
during the positive inotropic response to calyculin A revealed no change in time to peak 
force nor the relaxation time compared to basal. These characteristics are typical of Gq-
mediated agonist responses as previously shown for e.g. 1-adrenergic receptors [84]. 
Especially the lack of a lusitropic effect is in sharp contrast to cAMP-mediated responses 
in the heart. 
 MLC-2 phosphorylation levels were also determined in the same muscle strips as 
inotropic responses were recorded, and the two variables were found to correlate. In 
parallel with the inotropic effect, calyculin A increased MLC-2 phosphorylation. ML-7 
alone did not significantly reduce phosphorylation levels compared to time-matched 
control, in contrast to the combination of ML-7 and calyculin A. A correlation between 
inotropic effect and MLC-2 phosphorylation levels has to our knowledge not previously 
been shown in ventricle, and is consistent with a key role for MLC-2 phosphorylation in 
mediating positive inotropic effects in muscle strips. 
The relevance of small MLC-2 phosphorylation differences  
The level of basal MLC-2 phosphorylation has been reported to vary widely, ranging 
from 5% to 46% in mammalian ventricular myocardium [33, 121, 124]. Several studies 
on contracting muscle strips have demonstrated an in situ basal MLC-2 phosphorylation 
level of about 20% [36, 37], corresponding nicely with our results. The maximal in vivo 
MLC-2 phosphorylation has been reported to be around 30-40% [20, 125]. In absolute 
numbers, such an increase appears small. However, the calyculin A-induced MLC-2 
phosphorylation in our cell culture model demonstrates a huge capacity of this signalling 
mechanism to respond to various neurohumoral stimuli. Reversible reactions in most 
biological systems display a maximum effect of 80%. Assuming the phosphorylation of 
MLC-2 follows the Michaelis-Menten equation, the steepest part of the phosphorylation 
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curve is between 20% and 80% phosphorylation.  In this interval, small differences in 
kinase activity cause relatively large changes in phosphorylation, and are therefore most 
suited for regulation in a biological system. Likewise, if contractile force is plotted 
against MLC-2 phosphorylation levels, and the regulation is set on the steepest part of the 
curve, even minor changes in phosphorylation levels could give substantial effects. 
Agonist effects in contracting cells and muscle strips 
Paper IV demonstrated that activation of muscarinic M2 receptors elicited positive 
inotropic effects in muscle strips from rat ventricle with heart failure and not in sham-
operated animals. These effects were found to be mediated by MLC-2 phosphorylation 
by direct regulation of MLCK and indirect regulation of MLCP through Rho kinase. 
Inhibiting Rho kinase and MLCK separately attenuated the inotropic response by roughly 
the same magnitude (~70% reduction), and the increase in MLC-2 phosphorylation 
accompanying carbachol stimulation was abolished by both blockers separately.  
 Inotropic responses to muscarinic agonists in the heart have previously been 
reported in both normal human ventricular trabeculae [126], guinea pig papillary muscles 
[127, 128], embryonic chick ventricle [129, 130] and rat atria [128, 131], but this is the 
first report of such in the rat ventricle. Additionally, in normal rat heart, carbachol has 
been found to increase Ca2+ sensitivity with no apparent corresponding inotropic 
response [132, 133].  
 The muscarinic M2 response was in paper IV characterized by a biphasic inotropic 
response composed of an initial relatively fast transient negative component followed by 
a slowly developing positive component. Also, it displayed a symmetrical change in the 
contraction-relaxation cycle with slightly prolonged time to peak tension and relaxation 
time. These are all typical features of effects mediated through Gq-coupled receptors, 
known to elicit Ca2+-sensitization of the myofilaments [133] as seen with stimulation of 
1-adrenoceptors [34, 123, 134], 5-HT2A- [37] and endothelin receptors [35], in addition 
to the calyculin A-induced MLC-2 phosphorylation observed in paper III. Gq is known to 
activate the Rho kinase pathway [135] exerting its effects through MLCP inhibition, thus 
increasing MLC-2 phosphorylation [96]. Y27632, a selective Rho kinase inhibitor, 
attenuated the carbachol-mediated positive inotropic effect and MLC-2 phosphorylation 
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when added before carbachol. In contrast, Y27632 did not inhibit the cAMP-dependent -
adrenoceptor-mediated inotropic response, consistent with previous findings [34, 37]. 
ML-9, which inhibits MLCK and Rho kinase to the same degree, had about the same 
effect as Y27632 upon the inotropic response and MLC-2 phosphorylation, indicating 
that these effects are mediated also through MLCK activity. 
 However, the fact that the carbachol-mediated positive inotropic response was 
Pertussis toxin-sensitive lends support to a signalling pathway going through Gi. Perhaps 
there is a switch in signalling pathways in the transition from normal to failing rat 
ventricle like reported in neonatal rat cardiomyocyte-derived H10 cells [136]. Using a 
less energy-demanding mechanism of inotropic support may be advantageous in the 
failing heart, as compared to cAMP-mediated mechanisms. An enhancement in Ca2+ 
sensitivity is therefore a reasonable method of doing so, but clearly further investigations 
are needed to clarify the functional role of carbachol-mediated inotropic response and 
which signalling mechanisms are involved. 
 Electrically stimulated cardiomyocytes (paper III) were treated with three 
different agonists. These were phenylephrine, fluprostenol and carbachol, acting on 1- 
adrenergic, prostanoid F and muscarinic M2 receptors, respectively. Agonist stimulation 
in the presence of calyculin A did not increase MLC-2 phosphorylation beyond the effect 
of calyculin A alone, although a tendency towards a slight elevation with phenylephrine 
and fluprostenol was observed. This led us to believe that agonist effects might be acting 
predominantly through modulation of MLCP activity, but agonist stimulation in the 
absence of calyculin A did not significantly increase MLC-2 phosphorylation, rendering 
the question rather open. The lack of effect of carbachol was, however, in line with what 
was observed in carbachol-stimulated muscle strips from sham operated animals (paper 
IV). 
 In the presence of calyculin A, ML-7 preincubation reduced MLC-2 
phosphorylation levels in cardiomyocytes more when combined with agonists than 
without. This slight increase in ML-7 sensitivity is indicative of an increased MLCK 
activity in the presence of phenylephrine and fluprostenol. One might speculate if these 
agonists initiate signalling pathways increasing MLCK activity without being reflected in 
increased MLC-2 phosphorylation per se. Alternatively, lack of agonist effects could be 
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the result of a methodological problem if the collagenase treatment during the isolation 
procedure disturbed the receptors or in worst case peeled off the receptors. Further 
experiments are definitely needed to clarify agonist effects in electrically stimulated 
cardiomyocytes. 
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SUMMARY AND CONCLUSIONS 
In the papers presented in this thesis we have investigated several aspects of MLC-2 
phosphorylation, its regulation and significance in modulating cardiac contractility. 
Firstly, we presented a novel method for calculating reaction rate constants, demonstrated 
how to employ it and thus evaluate enzyme inhibitor efficacy. Secondly, quiescent 
cardiomyocytes were compared to electrically stimulated cells with respect to kinase 
activities involved in the phosphorylation of MLC-2. CaMKII was found to play a key 
role in this phosphorylation reaction when the cells are not contracting, but MLCK 
dominates when the cells contract. Furthermore, unidentified kinase activities were also 
detected, both Ca2+/calmodulin-dependent and –independent present in quiescent cells, 
and Ca2+/calmodulin-independent present in contracting cells. Agonist stimulation of 
contracting cells did not significantly elevate MLC-2 phosphorylation, but muscarinic M2 
receptor stimulation was found to be mediated through MLC-2 phosphorylation in 
muscle strips from failing rat hearts. Additionally, calyculin A-induced positive inotropic 
effects in normal rat ventricle strips were also found to be mediated through MLC-2 
phosphorylation. Finally, after using three different model systems (quiescent cells, 
contracting cells and contracting muscle strips), we observed apparent differences 
between the different models with respect to agonist stimulation and regulation of the 
level of MLC-2 phosphorylation. This indicates that the regulation of the MLC-2 
phosphorylation level is very dynamic and difficult to reveal. The results also indicate 
that several enzymes together serve to guarantee at least a certain minimum level of 
MLC-2 phosphorylation during various conditions. The study as a whole clearly 




The current research has revealed new aspects of how contractile function is regulated, 
but it has also triggered several new questions which would be highly interesting to 
pursue. The most intriguing question is how different kinases seem to switch between 
different activity levels depending on the state of the cell. In future studies, it would be 
interesting to further investigate which kinases are involved in the various model systems 
used for the study of the intact beating heart in vivo. Clearly, there are essential 
differences depending on whether the model is e.g. cells or tissue, neonatal or adult, 
normal or failing. One way of approaching this question would be to knock out all 
MLCK isoforms in the heart, and see whether other kinases would take over in 
electrically stimulated cells thus behaving like quiescent cells with respect to MLC-2 
phosphorylation activity. On the other hand, as such an intervention could be detrimental 
at an early stage in the development of the animal due to no sarcomere assembly and 
formation and therefore disintegrated cells, this might necessitate the use of inducible 
knock-out. 
 Now when a cardiac MLCK has been described, several issues have to be 
resolved. Considering whether cMLCK is Ca2+-dependent or not, is one basic question. 
An overwhelming amount of literature states that rat smMLCK and skMLCK are Ca2+-
regulated, and one study states that rat cMLCK is not [51]. The selectivity of inhibitors 
on cardiac isoforms needs to be clarified. If necessary, cardiac specific inhibitors should 
be designed.  
 The last three papers in this thesis described MLC-2 kinase activity in various 
model systems. However, the regulation of MLC-2 phosphorylation by phosphatase 
activity is also highly interesting, but was beyond the scope of this work. MYPT2, the 
regulatory subunit of cMLCP, has several phosphorylation sites displaying both 
stimulatory and inhibitory actions upon MLC-2 phosphorylation. As indicated in paper I, 
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the dephosphorylation reaction is by far the dominating in basal steady-state equilibrium 
therefore representing an enormous regulatory potential.  
 Further studies are also needed to resolve whether there are multiple functionally 
important phosphorylation sites on MLC-2. The protein contains several serine and 
threonine residues representing potential sites for phosphorylation. Mice expressing non-
phosphorylatable MLC-2 have been made [43], and it will be exciting to see the results of 
e.g. functional contraction studies, agonist effects, and possible compensatory 
mechanisms on these animals. It is also important to look towards other sarcomeric 
proteins, with respect to their role and cooperativity in regulating cardiac contraction. 
Some of these proteins have only recently received attention, and much work remains. 
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